View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 27, 2022

Laekna doses first subjects in Phase Ib/III breast cancer therapy trial

The trial will analyse the safety and efficacy of afuresertib plus fulvestrant combination in HR+/HER2- breast cancer patients.

Laekna Therapeutics has dosed the first two subjects in the US and China, respectively, in a Phase Ib/III clinical trial of afuresertib plus fulvestrant in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients.

Subject enrolment was initiated at the same time at the Piedmont Cancer Institute in the US and Tianjin Medical University Cancer Institute & Hospital in China.

Afuresertib is an investigational inhibitor of AKT kinase, while fulvestrant is an estrogen receptor antagonist.

The company obtained worldwide exclusive rights to afuresertib from Novartis. 

The trial will analyse the safety and efficacy of afuresertib plus fulvestrant combination in HR+/HER2- breast cancer patients, who have failed one to two lines of treatments with CDK4/6 inhibitors, endocrine, or chemotherapy.

The company anticipates expanding the trial to various several other sites soon. 

Laekna Therapeutics chief medical officer Dr Yong Yue said: “Our team has been working closely with the investigators to overcome obstacles and dose the first patients both in the US and China according to schedule, which demonstrated Laekna’s robust global clinical development capabilities. 

“Our next step is to expedite simultaneous global development of afuresertib plus fulvestrant to bring hope to patients who have developed treatment resistance.”

The company will commence a Phase III worldwide pivotal trial after a manageable safety profile of afuresertib plus fulvestrant combination therapy is demonstrated in the Phase Ib trial. 

The latest development comes after the company raised Series D funds worth $61m.

CS Capital led the funding round with Worldstar and Infinity Capital offering support. 

The proceeds from the financing round will be utilised to expedite the clinical development of the company product candidates, LAE002 and LAE001.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena